Walvax BioTech (300142)

Shenzhen
Currency in CNY
12.01
+0.06(+0.50%)
Closed
300142 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
11.8112.04
52 wk Range
9.7819.18
Key Statistics
Edit
Bid/Ask
12.00 / 12.01
Prev. Close
11.95
Open
11.9
Day's Range
11.81-12.04
52 wk Range
9.78-19.18
Volume
20.38M
Average Volume (3m)
25.07M
1-Year Change
-32.54%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
300142 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
11.00
Downside
-8.41%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Walvax BioTech Company Profile

Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococcal polysaccharide vaccine, for individuals age 2 years of pneumococcal diseases; ACYW135 meningococcal polysaccharide vaccine, for the prevention of invasive meningococcal diseases; Group A and C meningococcal polysaccharide vaccine, for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium neisseria meningitidis; Group A and Group C meningococcal conjugate vaccine, for the prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children 3 months through 5 years of age. It also provides haemophilus influenzae type b conjugate vaccine, for the prevention of invasive infections for children 2 months through 5 years of age; diphtheria, tetanus, and acellular pertussis combined vaccine, for diphtheria and tetanus for infants and children 3 months through 6 years of age. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.

Employees
2388
Market
China

Compare 300142 to Peers and Sector

Metrics to compare
300142
Peers
Sector
Relationship
P/E Ratio
155.1x25.9x−0.6x
PEG Ratio
−1.870.130.00
Price/Book
2.0x1.7x2.6x
Price / LTM Sales
6.1x5.7x3.1x
Upside (Analyst Target)
−7.9%25.7%52.8%
Fair Value Upside
Unlock12.6%8.4%Unlock

Analyst Ratings

0 Buy
0 Hold
1 Sell
Ratings:
1 analysts
Overall Consensus
Sell

Analysts 12-Month Price Target:

Average 11.00
(-8.41% Downside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.077
Dividend Yield
0.08%
Industry Median 1.40%
Annualized payout
0.0100
Paid annually
5-Years Growth
-19.73%
Growth Streak

Earnings

Latest Release
Oct 24, 2024
EPS / Forecast
0.05 / 0.06
Revenue / Forecast
708.00M / 1.04B
EPS Revisions
Last 90 days

FAQ

What Is the Walvax BioTech (300142) Stock Price Today?

The Walvax BioTech stock price today is 12.01

What Stock Exchange Does Walvax BioTech Trade On?

Walvax BioTech is listed and trades on the Shenzhen stock exchange.

What Is the Stock Symbol for Walvax BioTech?

The stock symbol for Walvax BioTech is "300142."

Does Walvax BioTech Pay Dividends? What’s The Current Dividend Yield?

The Walvax BioTech dividend yield is 0.08%.

What Is the Walvax BioTech Market Cap?

As of today, Walvax BioTech market cap is 19.21B.

What is Walvax BioTech Earnings Per Share?

The Walvax BioTech EPS is 0.077.

What Is the Next Walvax BioTech Earnings Date?

Walvax BioTech will release its next earnings report on Mar 21, 2025.

From a Technical Analysis Perspective, Is 300142 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.